Sökning: WFRF:(Wahlquist Rolf)
> (2007) >
Analysis of progres...
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer
-
- Gårdmark, Truls (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Gårdmark, T., Department of Urology, Surgical Sciences, Uppsala, Sweden
-
- Jahnson, Staffan (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Kirurgi,Urologiska kliniken i Östergötland
-
- Wahlquist, Rolf (författare)
- Department of Urology, Surgical Sciences, Oslo, Norway
-
visa fler...
-
- Wijkström, Hans (författare)
- Wijkström, H., Department of Urology, Surgical Sciences, Stockholm, Sweden
-
- Malmström, Per-Uno (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Malmström, P.-U., Department of Urology, Surgical Sciences, Uppsala, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2007
- 2007
- Engelska.
-
Ingår i: BJU International. - 1464-4096 .- 1464-410X. ; 99:4, s. 817-820
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up. Patients and methods: Between 1987 and 1992, 261 patients were included; they had frequently recurring Ta/T1G1–G2, T1G3 or primary Tis-dysplasia. The patients were randomized to treatment with either 40 mg of MMC or 120 mg of BCG (Danish strain 1331) given weekly for 6 weeks, then monthly up to a year and finally every third month for a further year. The 250 evaluable patients were followed using hospital files and national registers on causes of death. Results: The median follow-up for survivors was 123 months. The disease progressed in 58 (23%) of the patients, 34 in the MMC group and 24 in the BCG group (P = 0.26). Of the 140 patients who died, 68 were in the BCG and 72 in the MMC group (log-rank P = 0.98); most (95, 68%) died from other causes. Conclusion: Based on the follow-up of the present patients it cannot be concluded that the drugs originally administered, MMC or BCG, differed in their effect on progression, need for subsequent treatment or survival.
Nyckelord
- Administration; Intravesical
- Adult
- Aged
- Aged; 80 and over
- Antibiotics; Antineoplastic/therapeutic use
- Antineoplastic Agents/*therapeutic use
- BCG Vaccine/*therapeutic use
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Mitomycin/*therapeutic use
- Neoplasm Recurrence; Local/prevention & control
- Neoplasm Staging
- Prospective Studies
- Risk Factors
- Survival Analysis
- Treatment Outcome
- Urinary Bladder Neoplasms/*drug therapy/mortality
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas